Known targets — ChEMBL curated mechanism
FGFR3FLT1FLT3FLT4KDRKITPDGFRAPDGFRB
The experimentally established mechanism targets of Dovitinib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDGFRB known ✓ | P09619 | 17/20 | 0.86 |
| ▸ | KDR known ✓ | P35968 | 17/20 | 0.86 |
| ▸ | FLT1 known ✓ | P17948 | 4/20 | 0.86 |
| ▸ | FLT3 known ✓ | P36888 | 2/20 | 0.86 |
| ▸ | KIT known ✓ | P10721 | 1/20 | 0.86 |
| ▸ | PDGFRA known ✓ | P16234 | 1/20 | 0.86 |
| ▸ | FGFR3 known ✓ | P22607 | 1/20 | 0.86 |
| ▸ | FLT4 known ✓ | P35916 | 1/20 | 0.86 |
| ▸ | FGFR1 | P11362 | 19/20 | 0.86 |
| ▸ | LCK | P06239 | 2/20 | 0.86 |
| ▸ | MAP4K1 | Q92918 | 2/20 | 0.86 |
| ▸ | PLK4 | O00444 | 1/20 | 0.86 |
| ▸ | STK25 | O00506 | 1/20 | 0.86 |
| ▸ | CIT | O14578 | 1/20 | 0.86 |
| ▸ | RIOK3 | O14730 | 1/20 | 0.86 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.86 |
| ▸ | GAK | O14976 | 1/20 | 0.86 |
| ▸ | CHUK | O15111 | 1/20 | 0.86 |
| ▸ | MUSK | O15146 | 1/20 | 0.86 |
| ▸ | EPHB6 | O15197 | 1/20 | 0.86 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Dovitinib SCHEMBL30567813 | 1.00 | FGFR1 (0.86) | FGFR1PDGFRBKDRFLT1LCK | |
| Dovitinib SCHEMBL12003201 | 0.99 | FGFR1 (0.85) | FGFR1PDGFRBKDRFLT1LCK | |
| Dovitinib SCHEMBL29424010 | 0.93 | FGFR1 (1.00) | FGFR1PDGFRBKDRFLT1LCK | |
| Dovitinib SCHEMBL172687 | 0.93 | FGFR1 (1.00) | FGFR1PDGFRBKDRFLT1LCK | |
| Dovitinib SCHEMBL29352967 | 0.93 | FGFR1 (1.00) | FGFR1PDGFRBKDRFLT1LCK | |
| Dovitinib SCHEMBL946022 | 0.93 | FGFR1 (0.75) | FGFR1PDGFRBKDRFLT1LCK | |
| Dovitinib SCHEMBL945391 | 0.92 | FGFR1 (0.73) | FGFR1PDGFRBKDRFLT1LCK | |
| Dovitinib SCHEMBL248083 | 0.92 | FGFR1 (0.98) | FGFR1PDGFRBKDRFLT1LCK | |
| SCHEMBL14818888 | 0.91 | FGFR1 (0.71) | FGFR1PDGFRBKDRFLT1LCK | |
| SCHEMBL24233174 | 0.90 | FGFR1 (0.71) | FGFR1PDGFRBKDRFLT1LCK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 293 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150202203-A1 | Method of Treating Gastrointestinal Stromal Tumors | NOVARTIS AG (CH) | 2015-07-23 | — | — | US | claimed |
| US-20140378422-A1 | Combination of a RTK inhibitor with an anti-estrogen and use thereof for the treatment of cancer | NOVARTIS AG (CH) | 2014-12-25 | — | — | US | claimed |
| EP-2809312-A1 | COMBINATION OF A RTK INHIBITOR WITH AN ANTI - ESTROGEN AND USE THEREOF FOR THE TREATMENT OF CANCER | Novartis AG (CH) | 2014-12-10 | — | — | EP | claimed |
| EP-2257544-B1 | CRYSTALLINE FORMS AND TWO SOLVATED FORMS OF 4-AMINO-5-FLUORO-3-[5-(4-METHYLPIPERAZIN-1-YL)-1H-BENZIMIDAZOL-2-YL]QUINOLIN-2(1H)-ONE LACTIC ACID SALTS | NOVARTIS AG (CH) | 2014-12-03 | — | — | EP | claimed |
| WO-2013116293-A1 | COMBINATION OF A RTK INHIBITOR WITH AN ANTI - ESTROGEN AND USE THEREOF FOR THE TREATMENT OF CANCER | NOVARTIS AG (CH) | 2013-08-08 | — | — | WO | claimed |
| EP-2573079-A2 | Benzimidazole quinolinones and uses thereof | Novartis Vaccines and Diagnostics, Inc. (US) | 2013-03-27 | — | — | EP | claimed |
| EP-2309987-B1 | MELT GRANULATION PROCESS | NOVARTIS AG (CH) | 2012-08-29 | — | — | EP | claimed |
| EP-1497287-B1 | Quinoline derivatives in combination with 5-FU or CPT-11 for use in the treatment of cancer | NOVARTIS VACCINES & DIAGNOSTIC (US) | 2010-11-24 | — | — | EP | claimed |
| US-20100272717-A1 | COMBINATIONS OF THERAPEUTIC AGENTS FOR TREATING CANCER | NOVARTIS AG (CH) | 2010-10-28 | — | — | US | claimed |
| US-20100184754-A1 | QUINOLINONE DERIVATIVES | NOVARTIS VACCINES AND DIAGNOSTICS, INC. | 2010-07-22 | — | — | US | claimed |
| US-20080070906-A1 | QUINOLINONE DERIVATIVES | NOVARTIS VACCINES AND DIAGNOSTICS, INC. | 2008-03-20 | — | — | US | claimed |
| US-7335774-B2 | Quinolinone derivatives | NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) | 2008-02-26 | — | — | US | claimed |
| EP-1650203-B1 | Process of preparation of benzimidazol-2-yl quinolinone derivatives | NOVARTIS VACCINES & DIAGNOSTIC (US) | 2008-02-20 | — | — | EP | claimed |
| WO-2007056317-A2 | METHODS FOR ASSAYING AN ACTIVE PHARMACEUTICAL INGREDIENT | NOVARTIS VACCINES & DIAGNOSTICS, INC. (US) | 2007-05-18 | — | — | WO | claimed |
| EP-1650203-A1 | Process of preparation of benzimidazol-2-yl quinolinone derivatives | CHIRON CORPORATION (US) | 2006-04-26 | — | — | EP | claimed |
| EP-1317442-B1 | QUINOLINONE DERIVATIVES AS TYROSINE KINASE INHIBITORS | CHIRON CORP (US) | 2005-11-16 | — | — | EP | claimed |
| US-20050209456-A1 | Vascular endothelial growth factor; tyrosine kinase inhibitor; angiogenesis inhibitor; anticancer agents | CHIRON CORPORATION | 2005-09-22 | — | — | US | claimed |
| US-20050054672-A1 | Vascular endothelial growth factor; tyrosine kinase inhibitor;angiogenesis inhibitor; anticarcinogenic agents | CHIRON CORPORATION | 2005-03-10 | — | — | US | claimed |
| US-6774237-B2 | VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR TYROSINE KINASES INHIBITORS; ANGIOGENESIS INHIBITORS, ANTICARCINOGENIC AGENTS | CHIRON CORPORATION | 2004-08-10 | — | — | US | claimed |
| US-20030158224-A1 | Quinolinone derivatives | CHIRON CORPORATION | 2003-08-21 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080070906-A1 | QUINOLINONE DERIVATIVES | SLCO1B1, SLCO1B3, SLCO1A2 | PDGFRB 4032/4885KDR 4147/4885FLT1 4072/4885 |
| US-20100272717-A1 | COMBINATIONS OF THERAPEUTIC AGENTS FOR TREATING CANCER | ANXA5, BAX, ANXA6 | PDGFRB 2558/4885KDR 56/4885FLT1 419/4885 |
| US-20140378422-A1 | Combination of a RTK inhibitor with an anti-estrogen and use thereof for the treatment of cancer | ERBB2, EGFR, RET | PDGFRB 83/4885KDR 27/4885FLT1 37/4885 |
| US-20050054672-A1 | Vascular endothelial growth factor; tyrosine kinase inhibitor;angiogenesis inhibitor; anticarcinogenic agents | VEGFA, FLT1, KDR | PDGFRB 49/4885KDR 3/4885FLT1 2/4885 |
| US-20030158224-A1 | Quinolinone derivatives | SLCO1B1, SLCO1B3, SLCO1A2 | PDGFRB 4039/4885KDR 4038/4885FLT1 3748/4885 |
| US-20050209456-A1 | Vascular endothelial growth factor; tyrosine kinase inhibitor; angiogenesis inhibitor; anticancer agents | KDR, FLT4, FLT1 | PDGFRB 26/4885KDR 1/4885FLT1 3/4885 |
| US-20100184754-A1 | QUINOLINONE DERIVATIVES | SLCO1B1, SLCO1B3, SLCO1A2 | PDGFRB 4032/4885KDR 4147/4885FLT1 4072/4885 |
| US-20150202203-A1 | Method of Treating Gastrointestinal Stromal Tumors | KIT, FGFR2, FGFR3 | PDGFRB 7/4885KDR 32/4885FLT1 24/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.